Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
08
2018
accepted:
16
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
13
11
2019
Statut:
epublish
Résumé
Liver cirrhosis is associated with profound immunodysfunction, i.e. a parallel presence of chronic systemic inflammation and immunosuppression, which can result in acute-on-chronic liver failure (ACLF). Omega-3 fatty acids are precursors of pro-resolving mediators and support the resolution of inflammation. The aim of this study was to determine plasma levels of omega-3 fatty acids in patients with liver cirrhosis and ACLF. Patients with liver cirrhosis with and without ACLF were enrolled in a prospective cohort study and analyzed post-hoc for the present sub-study. Clinical data and biomaterials were collected at baseline and at day 7, 28 and after 3 months of follow-up. Plasma concentrations of arachidonic acid (ARA) and docosahexaenoic acid (DHA), which represent key omega-6 and -3 fatty acids, respectively, were quantified and associated with markers of systemic inflammation and severity of liver cirrhosis. A total of 117 patients were included in the present analyses. Of those, 26 (22.2%), 51 (43.6%) and 40 (34.2%) patients had compensated or decompensated liver cirrhosis, and ACLF. Plasma levels of ARA and DHA were similar in patients with compensated cirrhosis, decompensated cirrhosis, and ACLF. Furthermore, no significant association between plasma ARA or DHA and C-reactive protein or peripheral blood leukocytes were observed (P>0.05). In our study plasma levels of key omega-3 and omega-6 fatty acid are neither associated with the severity of liver cirrhosis nor with liver-cirrhosis-associated systemic inflammation.
Sections du résumé
BACKGROUND
Liver cirrhosis is associated with profound immunodysfunction, i.e. a parallel presence of chronic systemic inflammation and immunosuppression, which can result in acute-on-chronic liver failure (ACLF). Omega-3 fatty acids are precursors of pro-resolving mediators and support the resolution of inflammation.
OBJECTIVE
The aim of this study was to determine plasma levels of omega-3 fatty acids in patients with liver cirrhosis and ACLF.
METHODS
Patients with liver cirrhosis with and without ACLF were enrolled in a prospective cohort study and analyzed post-hoc for the present sub-study. Clinical data and biomaterials were collected at baseline and at day 7, 28 and after 3 months of follow-up. Plasma concentrations of arachidonic acid (ARA) and docosahexaenoic acid (DHA), which represent key omega-6 and -3 fatty acids, respectively, were quantified and associated with markers of systemic inflammation and severity of liver cirrhosis.
RESULTS
A total of 117 patients were included in the present analyses. Of those, 26 (22.2%), 51 (43.6%) and 40 (34.2%) patients had compensated or decompensated liver cirrhosis, and ACLF. Plasma levels of ARA and DHA were similar in patients with compensated cirrhosis, decompensated cirrhosis, and ACLF. Furthermore, no significant association between plasma ARA or DHA and C-reactive protein or peripheral blood leukocytes were observed (P>0.05).
CONCLUSION
In our study plasma levels of key omega-3 and omega-6 fatty acid are neither associated with the severity of liver cirrhosis nor with liver-cirrhosis-associated systemic inflammation.
Identifiants
pubmed: 30703151
doi: 10.1371/journal.pone.0211537
pii: PONE-D-18-23843
pmc: PMC6355116
doi:
Substances chimiques
Biomarkers
0
Fatty Acids, Omega-3
0
Fatty Acids, Omega-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211537Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
J Hepatol. 2014 Jun;60(6):1310-24
pubmed: 24530646
Biomed Pharmacother. 2002 Oct;56(8):365-79
pubmed: 12442909
Hepatology. 2003 Jul;38(1):258-66
pubmed: 12830009
Dig Liver Dis. 2014 Jul;46(7):632-8
pubmed: 24703705
Lipids Health Dis. 2017 Mar 1;16(1):51
pubmed: 28249586
Lancet. 1999 Aug 7;354(9177):447-55
pubmed: 10465168
Nat Med. 2014 May;20(5):518-23
pubmed: 24728410
Am J Clin Nutr. 1997 Apr;65(4):1011-7
pubmed: 9094887
Semin Arthritis Rheum. 1997 Oct;27(2):85-97
pubmed: 9355207
J Nutr. 2013 Mar;143(3):315-23
pubmed: 23303872
Cell. 2010 Sep 3;142(5):687-98
pubmed: 20813258
Clin Gastroenterol Hepatol. 2018 May;16(5):633-636
pubmed: 29246698
Nat Rev Immunol. 2015 Aug;15(8):511-23
pubmed: 26139350
Sci Rep. 2016 Jul 20;6:30029
pubmed: 27435808
Am J Gastroenterol. 2001 Jul;96(7):1968-76
pubmed: 11467622
Lancet. 1994 Jun 11;343(8911):1454-9
pubmed: 7911176
Nat Rev Drug Discov. 2016 Aug;15(8):551-67
pubmed: 27020098
J Clin Med. 2016 Jan 26;5(2):
pubmed: 26821053
Nutrients. 2010 Mar;2(3):355-74
pubmed: 22254027
Hepatology. 2016 Oct;64(4):1249-64
pubmed: 27483394
Dig Dis Sci. 2011 Apr;56(4):1065-74
pubmed: 20848203
Medicine (Baltimore). 2018 Sep;97(37):e12271
pubmed: 30212963
J Clin Biochem Nutr. 2013 Jul;53(1):49-54
pubmed: 23874070
J Lipid Res. 2015 Sep;56(9):1808-20
pubmed: 26180051
Gastroenterology. 2015 Mar;148(3):603-615.e14
pubmed: 25479139